Orion Porfolio Solutions LLC Buys 66,112 Shares of Kenvue Inc. $KVUE

Orion Porfolio Solutions LLC lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 30.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 283,590 shares of the company’s stock after purchasing an additional 66,112 shares during the period. Orion Porfolio Solutions LLC’s holdings in Kenvue were worth $5,936,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Truvestments Capital LLC bought a new position in Kenvue during the first quarter valued at $37,000. Trust Co. of Vermont lifted its position in shares of Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the last quarter. Ransom Advisory Ltd bought a new position in shares of Kenvue during the 1st quarter worth $56,000. First Pacific Financial bought a new position in shares of Kenvue during the 2nd quarter worth $54,000. Finally, UMB Bank n.a. increased its holdings in Kenvue by 22.3% in the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock worth $60,000 after acquiring an additional 521 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent research reports. Evercore ISI set a $18.00 price objective on shares of Kenvue in a report on Tuesday, October 28th. Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Bank of America cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $15.00 target price (down previously from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.23.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $17.20 on Tuesday. The company has a 50 day moving average of $16.23 and a 200 day moving average of $19.01. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $32.94 billion, a P/E ratio of 22.93 and a beta of 0.59. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Insider Buying and Selling

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the purchase, the director directly owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by insiders.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.